Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Abstract Background Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new antidiabetic drug classes remains unclear. We therefore performed a net...
Main Authors: | Yue Fei, Man-Fung Tsoi, Bernard Man Yung Cheung |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0916-z |
Similar Items
-
Cardiovascular outcomes of antidiabetic drugs
by: Ranjit Kumar Nath, et al.
Published: (2021-03-01) -
The Selection of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients with High Risk for Cardiovascular Events
by: Derlin J. Leander, et al.
Published: (2020-12-01) -
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
by: Chris Wai Hang Lo, et al.
Published: (2021-03-01) -
COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
by: TRI MURTI ANDAYANI, et al.
Published: (2007-01-01) -
A new class of potential antidiabetic acetohydrazides: Synthesis, in vivo antidiabetic activity and molecular docking studies
by: Mubeen Arif, et al.
Published: (2017-09-01)